A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
Crossref DOI link: https://doi.org/10.1007/s00280-014-2594-6
Published Online: 2014-09-25
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Slingerland, Marije
Hess, Dagmar
Clive, Sally
Sharma, Sunil
Sandstrom, Per
Loman, Niklas
Porro, Maria G.
Mu, Song
Waldron, Edward
Valera, Sue-zette
Gelderblom, Hans
Text and Data Mining valid from 2014-09-25